NATCOPHARM.NS NSE
Natco Pharma Limited
1W: -1.7%
1M: -3.3%
3M: -11.8%
YTD: -2.9%
1Y: -9.0%
3Y: -6.2%
5Y: -13.2%
₹819.00 ($8.50)
-8.50 (-1.03%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$17.7B
+4.2% ▲
5Y CAGR: +42.7%
Capital Expenditures
$3.9B
+2.5% ▲
5Y CAGR: +9.0%
Free Cash Flow
$13.8B
-3.6% ▼
5Y CAGR: +98.9%
Dividends Paid
$902M
+16.3% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$789M
+59.1% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $2.0B | $8.6B | $13.9B | $18.9B | $14.9B |
| Depreciation & Amort. | $1.4B | $1.6B | $1.9B | $2.4B | $2.1B |
| Stock-Based Comp. | $22M | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$2.3B | $627M | -$3.1B | -$2.0B | $6.5B |
| Other Non-Cash Items | -$229M | -$2.4B | -$541M | -$2.2B | -$5.7B |
| Operating Cash Flow | $465M | $8.5B | $12.1B | $17.0B | $17.7B |
| — Investing Activities — | |||||
| Capital Expenditures | -$2.4B | -$2.1B | -$3.4B | -$5.1B | -$3.9B |
| Acquisitions (Net) | -$1.0B | $201M | $0 | $950M | -$20.9B |
| Investment Purchases | -$913M | -$5.4B | -$11.9B | -$28.4B | -$57.4B |
| Investment Sales | $3.0B | $1.1B | $5.8B | $16.8B | $60.8B |
| Other Investing | $1.4B | $1.4B | -$898M | $1.7B | $521M |
| Investing Cash Flow | -$53M | -$4.8B | -$10.3B | -$14.1B | -$20.8B |
| — Financing Activities — | |||||
| Net Debt Issuance | -$24M | -$2.4B | $2.0B | -$892M | $4.3B |
| Stock Repurchased | $0 | -$74M | -$2.5B | $0 | $0 |
| Dividends Paid | -$822M | -$1.0B | -$1.7B | -$1.1B | -$902M |
| Other Financing | $1.2B | -$162M | -$202M | -$210M | -$383M |
| Financing Cash Flow | $348M | -$3.6B | -$2.5B | -$2.1B | $3.0B |
| Net Change in Cash | $853M | $208M | -$615M | $496M | $789M |
| Cash End of Period | $1.1B | $1.3B | $704M | $1.2B | $2.0B |
| Free Cash Flow | -$2.0B | $6.4B | $8.7B | $14.3B | $13.8B |